Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia

Kidney International

Volumn 55, Issue 6, 1999, Pages 2477-2486

  Tarng, Der Cherng ^a   Yau Huei, Wei ^a   Huang, Tung Po ^a   Kuo, Benjamin I T ^a   Yang, Wu Chang ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anemia; Dialysis; Erythropoiesis; Iron overload; Transferrin saturation; Zinc protoporphyrin

Indexed keywords

ASCORBIC ACID; ERYTHROCYTE PROTOPORPHYRIN; FERRITIN; IRON; PROTOPORPHYRIN ZINC; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERFERRITINEMIA; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON KINETICS; IRON METABOLISM; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032993461     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00479.x     Document Type: Article

References (53)

1. 1. Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Yin JA, Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
2. 2. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1993
3. 3. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW: USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76:160-165, 1989
4. 4. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. V. Inadequate epoietin response. Am J Kidney Dis 30(Suppl 3):S218-S220, 1997
5. 5. Ali M, Fayemi AO, Rigilosi R, Francino J, Marsden T, Malcolm D: Hemosiderosis in hemodialysis patients. JAMA 244:343-345, 1980
6. 6. Kotharis T, Swamy AP, Lee JCK, Mangla JC, Cestero RVM: Hepatic hemosiderosis in maintenance hemodialysis patients. Dig Dis Sci 25:363-368, 1980
7. 7. Tomson CRV: Erythropoietin: What problems remain in 1994? Nephrol Dial Transplant 9:344-345, 1994
8. 8. Baelaert JR, Daneels RF, Schurgers ML, Mathys EG, Gordts BZ, Van Landuyt HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5:130-134, 1990
9. 9. El-Reshaid K, Johny KV, Hakim A, Kamel H, Sebeta A, Hourani H, Kanyike FB: Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 91:130-135, 1994
10. 10. Ali M, Rigilosi R, Fayemi AO, Braun EV, Francino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1:652-655, 1982
11. 11. Macdougall IC, Cavill I, Hulme B, Brain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:225-226, 1992
12. 12. Tarng DC, Chen TW, Huang TP: Iron metabolism indices for early detection of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15: 230-237, 1995
13. 13. Tarng DC, Huang TP, Chen TW: Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Am J Nephrol 17:158-164, 1997
14. 14. Tarng; DC, Huang TP: A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hypo-responsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 13:2867-2872, 1998
15. 15. Goch J, Birgegǎrd G, Danielson BG, Wikström B: Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration. Eur J Haematol 55:73-77, 1995
16. 16. Banerjee S, Chakrabarty AS: Utilization of iron by scorbutic guinea pigs. Blood 25:839-844, 1965
17. 17. Bothwell TH, Bradlow BA, Jacobs B, Keeley K, Kramer S, Seftel H, Zalil S: Iron metabolism in scurvy with special reference to erythropoiesis. Br J Haemat 10:50-58, 1964
18. 18. Sullivan JF, Eisenstein AB: Ascorbic acid depletion in patients undergoing chronic hemodialysis. Am J Clin Nutr 23:1339-1346, 1970
19. 19. Pönkä A, Kuhlbäck B: Serum ascorbic acid in patients undergoing chronic hemodialysis. Acta Med Scand 213:305-307, 1983
20. 20. Alkhunaizi AM, Chan L: Secondary oxalosis: A cause of delayed recovery of renal function in the setting of acute renal failure. J Am Soc Nephrol 7:2320-2326, 1996
21. 21. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanher-Weghem JL, Tielemans C: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10(Suppl 6):44-47, 1995
22. 22. Goldberg A, Ashenbrucker H, Cartwright GE, Wintrobe MM: Studies on the biosynthesis of heme in vitro by avian erythrocytes. Blood 11:821-833, 1956
23. 23. Goldberg A: The enzymic formation of haem by the incorporation of iron into protoporphyrin: Importance of ascorbic acid, ergothioneine and glutathione. Br J Haemat 5:150-157, 1959
24. 24. Hastka J, Lasserre, J, Schwartzbeck A, Hehlmann R, Strauch M: Zinkprotoporphyrin als alternative zu ferritin bei Steuerung der eisensubstitution erythropoietin-bedürftiger dialyse-patienten. Nieren Hochdruckkrankh 20:697-700, 1991
25. 25. Zanella A, Gridelli L, Berzuini A, Colotti MT, Mozzi F, Milani S, Sirchia G: Sensitivity and predictive value of serum ferritin and free erythrocyte protoporphyrin for iron deficiency. J Lab Clin Med 113:73-78, 1889
26. 26. Fishbane S, Lynn RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25:426-432, 1995
27. 27. Schifman RB, Rivers SL, Finley PR,Thies C: RBC zinc protoporphyrin to screen blood donors for non deficiency anemia. JAMA 248:2012-2015, 1982
28. 28. Pru C, Eaton J, Kjellstrand C: Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 39:112-116, 1985
29. 29. Costello JF, Sadovnic MJ, Cottington EM: Plasma oxalate levels in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1:1289-1298, 1991
30. 30. Pan WH, Lee MM, Yu SL, Huang PC: Food predictive of nutrient intake in Chinese diet in Taiwan. II. Vitamin A, vitamin B1, vitamin B2, vitamin C and calcium. Int J Epidemiol 21:929-934, 1992
31. 31. Shifman RB, Finley PR: Measurement of near-normal concentrations of erythrocyte protoporphyrin with the hematofluorometer: Influence of plasma on "front-surface illumination" assay. Clin Chem 27:153-156, 1980
32. 32. Kyaw A: A simple colorimetric method for ascorbic acid determination in blood plasma, Clin Chem Acta 86:153-157, 1978
33. 33. Petrarulo M, Cerelli E, Marangella M, Cosseddu D, Vitale C, Linari F: Assay of plasma oxalate with soluble oxalate oxidase. Clin Chem 40:2030-2034, 1994
34. 34. Descombes E, Hanck AB, Fellay G: Water soluble vitamin in chronic hemodialysis patients and need for supplementation. Kidney Int 43:1319-1328, 1993
35. 35. Gilmour ER, Hartley GH, Goodship THJ: Trace elements and vitamins in renal diseases, in Nutrition and the Kidney, edited by Mitch WE, Klahr S, New York, Little Brown, 1993, pp 114-131
36. 36. Cotton AB: Routine vitamin therapy for the dialysis patient: Current concerns. Contemp Dial Nephrol 16:26-27, 1995
37. 37. Bothwell TH, Isaacson C: Siderosis in the Bantu: A comparison of incidence in males and females. BMJ 1:522-524, 1962
38. 38. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant erythropoietin: Results of phase I and II clinical trial. N Engl J Med 316:73-78, 1987
39. 39. Eschbach JW, Kelley MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
40. 40. Macdougall IC: Monitoring iron in patients on epoetin alfa. Iron Forum 2:1-13, 1996
41. 41. Bainton DF, Finch CA: The diagnosis of iron deficiency anemia. Am J Med 37:62-70, 1964
42. 42. Hörl WH, Cavill. I, Cove-Smith R, Eschbach J, Macdougall IC, Salmonson T, Schaefer RM, Sunder-Plassmann G: How to get the best out of r-HuEPO? Nephrol Dial Transplant 10(Suppl 2):92-95, 1995
43. 43. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during r-HuEPO therapy: A consensus report. Nephrol Dial Transplant 11:246-250, 1996
44. 44. Nissenson AR: Hyporesponsiveness to erythropoietin: Overview. Perit Dial Int 16:417-420, 1996
45. 45. Tarng DC, Huang TP: Hyporesponsiveness to erythropoietin. Perit Dial Int 17:99-100, 1997
46. 46. BRAUN J, HAMMERSCHMIDT M, SCHREIBER M, HEIDLER R, HöKI, WH: Is zinc protoporphyrin an indicator of iron-deficient erythro-poiesis in maintenance haemodialysis patients? Nephrol Dial Transplant 11:492-497, 1996
47. 47. Propper RD, Shurin SB, Nathan DG: Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294:1421-1423, 1976
48. 48. Nienhuis AW, Delea C, Aamodt R, Bartter F, Anderson WF: Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload. Birth Defects 12:177-185, 1976
49. 49. Aucella F, Vigilante M, Scalzulli P, Musto P, Crisetti A, Modoni S, Carotenuto M, Stallone C: Desferrioxamine improves burst-forming unit-erythroid(BFU-E)proliferation in haemodialysis patients. Nephrol Dial Transplant 13:1194-1199, 1998
50. 50. De La Serna FJ, Praga M, Gilsanz F, Rodicio JL, Ruliope LM, Alcazar JM: Improvement in the erythropoiesis of chronic hemodialysis patients with desferrioxamine. Lancet 1:1009-1011, 1988
51. 51. Henry W: Echocardiographic evaluation of the heart in thalassemia major. Ann Intern Med 91:892-894, 1979
52. 52. Jensen PD, Olsen N, Bagger JP, Jensen FT, Christensen T, Ellegaard J: Cardiac function during iron chelation therapy in adult non-thalassemic patients with transfusional iron overload. Eur J Haematol 59:221-230, 1997
53. 53. Berger TM, Polidor MC, Dabbagh A, Evans PJ, Halliwell B, Morrow JD, Roberts LJ, Frei B: Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem 272:15656-15660, 1997